Policy strategist Kristi Martin discusses how the Orphan Drug Act reshapes rare disease treatment and drug-pricing challenges ...

Oncodermatology is evolving with nonsurgical approaches and immune checkpoint inhibitors, improving outcomes in aggressive ...

PBMs typically receive a portion of rebates paid by drug manufacturers, the majority of which are passed back to the payer as an incentive to prefer a drug on a formulary. PBMs may also retain revenue ...

The Maui Derm 2026 meeting featured in-depth discussion surrounding all areas of dermatology. Here, The American Journal of Managed Care ® asked speakers and attendees what their ...

Explore the latest advancements in bispecific antibodies for multiple myeloma, focusing on early treatment opportunities and innovative trial designs.

Telomere length and polygenic risk scores (PRS) are linked to idiopathic pulmonary fibrosis (IPF) risk, especially in noncarriers of rare genetic variants. The study identified rare damaging variants ...

Na’ama Avitzur, MD, is a pulmonologist and a fellow at the University of British Columbia, researching interstitial lung disease and an internal medicine physician. A European Respiratory Journal ...

The Coalition’s Conversation podcast series is a 3-part discussion on how employers can incorporate glucagon-like peptide-1 (GLP-1) therapies into a sustainable strategy to address obesity and weight ...

The Orphan Drug Act revolutionized rare disease treatment, yet rising costs and access issues challenge equitable health care solutions.

While the cost of health care remains the dominant worry among Americans, the process of obtaining prior authorization from ...

Panelists discuss how advanced practice providers (APPs) play a central role in identifying and managing amyloid-related ...

Hair regrowth efficacy is the primary concern for AA patients, with insurance coverage and flare-up prevention also important ...